Annual EBITDA
-$243.72 M
-$30.03 M-14.05%
December 31, 2023
Summary
- As of February 7, 2025, RCKT annual EBITDA is -$243.72 million, with the most recent change of -$30.03 million (-14.05%) on December 31, 2023.
- During the last 3 years, RCKT annual EBITDA has fallen by -$117.82 million (-93.58%).
- RCKT annual EBITDA is now -4076.15% below its all-time high of -$5.84 million, reached on December 31, 2012.
Performance
RCKT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$63.86 M
+$2.94 M+4.41%
September 30, 2024
Summary
- As of February 7, 2025, RCKT quarterly EBITDA is -$63.86 million, with the most recent change of +$2.94 million (+4.41%) on September 30, 2024.
- Over the past year, RCKT quarterly EBITDA has dropped by -$4.19 million (-7.02%).
- RCKT quarterly EBITDA is now -6363.46% below its all-time high of -$988.00 thousand, reached on March 31, 2015.
Performance
RCKT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$247.25 M
-$4.19 M-1.72%
September 30, 2024
Summary
- As of February 7, 2025, RCKT TTM EBITDA is -$247.25 million, with the most recent change of -$4.19 million (-1.72%) on September 30, 2024.
- Over the past year, RCKT TTM EBITDA has dropped by -$2.32 million (-0.95%).
- RCKT TTM EBITDA is now -14233.16% below its all-time high of -$1.73 million, reached on December 31, 2013.
Performance
RCKT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RCKT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.1% | -7.0% | -0.9% |
| 3 y3 years | -93.6% | -7.0% | -0.9% |
| 5 y5 years | -253.5% | -7.0% | -0.9% |
RCKT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -54.4% | at low | -60.5% | +4.4% | -56.7% | at low |
| 5 y | 5-year | -243.8% | at low | -246.8% | +4.4% | -246.1% | at low |
| alltime | all time | -4076.2% | at low | -6363.5% | +4.4% | <-9999.0% | at low |
Rocket Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$63.86 M(-4.4%) | -$247.25 M(+1.7%) |
| Jun 2024 | - | -$66.80 M(+12.6%) | -$243.06 M(+1.4%) |
| Mar 2024 | - | -$59.33 M(+3.6%) | -$239.76 M(+1.3%) |
| Dec 2023 | -$243.72 M(+14.1%) | -$57.26 M(-4.0%) | -$236.62 M(-3.4%) |
| Sep 2023 | - | -$59.67 M(-6.0%) | -$244.93 M(+1.7%) |
| Jun 2023 | - | -$63.50 M(+13.0%) | -$240.77 M(+5.0%) |
| Mar 2023 | - | -$56.19 M(-14.3%) | -$229.24 M(+7.3%) |
| Dec 2022 | -$213.69 M(+35.4%) | -$65.56 M(+18.1%) | -$213.69 M(+13.7%) |
| Sep 2022 | - | -$55.52 M(+6.8%) | -$187.93 M(+4.1%) |
| Jun 2022 | - | -$51.98 M(+27.9%) | -$180.44 M(+11.9%) |
| Mar 2022 | - | -$40.64 M(+2.1%) | -$161.31 M(+2.2%) |
| Dec 2021 | -$157.81 M(+25.3%) | -$39.80 M(-17.1%) | -$157.81 M(-7.9%) |
| Sep 2021 | - | -$48.03 M(+46.3%) | -$171.28 M(+14.3%) |
| Jun 2021 | - | -$32.84 M(-11.6%) | -$149.84 M(+7.0%) |
| Mar 2021 | - | -$37.14 M(-30.3%) | -$140.00 M(+11.3%) |
| Dec 2020 | -$125.90 M(+77.6%) | -$53.27 M(+100.3%) | -$125.84 M(+38.3%) |
| Sep 2020 | - | -$26.60 M(+15.6%) | -$90.99 M(+10.8%) |
| Jun 2020 | - | -$23.01 M(+0.1%) | -$82.09 M(+7.4%) |
| Mar 2020 | - | -$22.97 M(+24.8%) | -$76.43 M(+7.0%) |
| Dec 2019 | -$70.89 M | -$18.41 M(+4.0%) | -$71.45 M(-9.6%) |
| Sep 2019 | - | -$17.70 M(+2.0%) | -$79.03 M(+3.8%) |
| Jun 2019 | - | -$17.35 M(-3.6%) | -$76.17 M(+4.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$17.99 M(-30.8%) | -$73.13 M(+6.0%) |
| Dec 2018 | -$68.95 M(+168.1%) | -$25.99 M(+75.2%) | -$69.01 M(+23.3%) |
| Sep 2018 | - | -$14.84 M(+3.7%) | -$55.95 M(+17.1%) |
| Jun 2018 | - | -$14.31 M(+3.2%) | -$47.78 M(+30.0%) |
| Mar 2018 | - | -$13.87 M(+7.2%) | -$36.74 M(+43.9%) |
| Dec 2017 | -$25.72 M(-37.7%) | -$12.94 M(+94.2%) | -$25.52 M(+3.7%) |
| Sep 2017 | - | -$6.66 M(+103.4%) | -$24.61 M(-13.7%) |
| Jun 2017 | - | -$3.28 M(+23.6%) | -$28.51 M(-15.9%) |
| Mar 2017 | - | -$2.65 M(-78.0%) | -$33.89 M(-17.9%) |
| Dec 2016 | -$41.27 M(-38.1%) | -$12.02 M(+13.8%) | -$41.27 M(+10.4%) |
| Sep 2016 | - | -$10.56 M(+22.1%) | -$37.38 M(-54.7%) |
| Jun 2016 | - | -$8.65 M(-13.8%) | -$82.58 M(+9.0%) |
| Mar 2016 | - | -$10.03 M(+23.3%) | -$75.75 M(+13.6%) |
| Dec 2015 | -$66.71 M(+680.1%) | -$8.13 M(-85.4%) | -$66.71 M(+10.3%) |
| Sep 2015 | - | -$55.76 M(+2960.5%) | -$60.48 M(+782.0%) |
| Jun 2015 | - | -$1.82 M(+84.4%) | -$6.86 M(-10.2%) |
| Mar 2015 | - | -$988.00 K(-48.1%) | -$7.63 M(-10.7%) |
| Dec 2014 | -$8.55 M(+27.0%) | -$1.90 M(-11.2%) | -$8.55 M(+2.1%) |
| Sep 2014 | - | -$2.14 M(-17.5%) | -$8.37 M(+34.4%) |
| Jun 2014 | - | -$2.60 M(+36.4%) | -$6.23 M(+71.6%) |
| Mar 2014 | - | -$1.91 M(+10.4%) | -$3.63 M(+110.4%) |
| Dec 2013 | -$6.73 M(+15.4%) | -$1.73 M | -$1.73 M |
| Dec 2012 | -$5.84 M | - | - |
FAQ
- What is Rocket Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Rocket Pharmaceuticals?
- What is Rocket Pharmaceuticals annual EBITDA year-on-year change?
- What is Rocket Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Rocket Pharmaceuticals?
- What is Rocket Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Rocket Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Rocket Pharmaceuticals?
- What is Rocket Pharmaceuticals TTM EBITDA year-on-year change?
What is Rocket Pharmaceuticals annual EBITDA?
The current annual EBITDA of RCKT is -$243.72 M
What is the all time high annual EBITDA for Rocket Pharmaceuticals?
Rocket Pharmaceuticals all-time high annual EBITDA is -$5.84 M
What is Rocket Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, RCKT annual EBITDA has changed by -$30.03 M (-14.05%)
What is Rocket Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of RCKT is -$63.86 M
What is the all time high quarterly EBITDA for Rocket Pharmaceuticals?
Rocket Pharmaceuticals all-time high quarterly EBITDA is -$988.00 K
What is Rocket Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, RCKT quarterly EBITDA has changed by -$4.19 M (-7.02%)
What is Rocket Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of RCKT is -$247.25 M
What is the all time high TTM EBITDA for Rocket Pharmaceuticals?
Rocket Pharmaceuticals all-time high TTM EBITDA is -$1.73 M
What is Rocket Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, RCKT TTM EBITDA has changed by -$2.32 M (-0.95%)